Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Biomarkers' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Mass Spectrometry in Protein Biomarker Applications Software, Services, and Instrument Markets |
November 2006 | £1980 | 100 % |
|
Biomarker Technology Platforms for Cancer Diagnoses and Therapies |
April 2008 | £2245 | 98 % |
|
Convergence of Biomarkers and Diagnostics, The Therapy Area Analyses, Key Products and Future Trends |
April 2008 | £1995 | 76 % |
|
Commercial Opportunities from Biomarkers Transforming drug discovery, clinical development and molecular diagnostic |
May 2006 | £1495 | 76 % |
|
Cardiac Biomarkers A Global Market Perspective |
November 2009 | £1980 | 76 % |
|
Biomarkers, Tests and Trends for Drug R&D |
February 2010 | £1450 | 75 % |
|
Biomarkers: Industry Background Report List of Companies |
October 2005 | £295 | 75 % |
|
Biomarkers: The Future of Next-Generation Drug R&D |
September 2008 | £1715 | 75 % |
|
Epigenomics Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics |
March 2007 | £3205 | 70 % |
|
Stakeholder Opinions: Diagnostics in Neurology Predictive Biomarkers Expand Drug Revenues |
July 2008 | £1320 | 70 % |
|
Biomarkers Technologies, Markets and Companies |
March 2010 | £2970 | 50 % |
|
Companion Biomarkers in Drug Development |
April 2009 | £2245 | 42.5 % |
|
Molecular Biomarkers Current Industry Sentiment and Future Trends |
January 2005 | £1945 | 35 % |
|
Alzheimer's Disease Biomarkers, 2009 |
January 2009 | £1499 | 30.1 % |
|
CNS Biomarkers: Players, products and prospects (Volume II) |
August 2008 | £595 | 29.4 % |
|
Biomarkers: A Market Briefing A Market Briefing |
January 2007 | £1320 | 28 % |
|
Cell Culture The World Market for Media, Sera, and Reagents |
January 2007 | £2575 | 28 % |
|
Cancer Biomarkers: Players, products and prospects (Volume I) |
August 2008 | £595 | 28 % |
|
Cardiovascular Biomarkers: Players, products and prospects (Volume III) |
August 2008 | £595 | 27.3 % |
|
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects |
August 2008 | £1495 | 26.6 % |
|
Innovations in Bioinformatics Emerging Tools for Drug Discovery and Development |
January 2008 | £1995 | 26 % |
|
Cancer Biomarkers: Adoption Is Driving Growth |
July 2008 | £2475 | 25.9 % |
|
BG Medicine, Inc. Product Pipeline Analysis |
August 2008 | £495 | 25.55 % |
|
Biomarkers in Drug Discovery Optimizing Drug Discovery Timeline and Costs |
February 2010 | £2310 | 22.4 % |
|
Orion Genomics Product Pipeline Analysis |
August 2008 | £495 | 19.6 % |
|
Translational Medicine In Biopharmaceutical R&d Enabling R&d Optimization And Early Detection Of Potential Failures |
October 2007 | £1495 | 18.55 % |
|
Cancer Biomarkers Enhancing diagnostic, therapeutic and developmental strategies |
May 2006 | £1450 | 17.85 % |
|
Pricing and Reimbursement: Innovative Risk-Sharing Strategies |
July 2009 | £2510 | 16.5 % |
|
Biomarkers The Expanding Global Market |
November 2007 | £3205 | 15.05 % |
|
Multiplex Assays Evolving Technologies, Applications and Future Directions |
December 2009 | £2475 | 15.05 % |
|
B·R·A·H·M·S Aktiengesellschaft Product Pipeline Analysis |
May 2008 | £495 | 13.3 % |
|
Epigenetics Technologies, Applications, and the Commercial Landscape |
February 2008 | £1240 | 12.95 % |
|
Molecular Diagnostics in Cancer Testing |
December 2009 | £2245 | 12.6 % |
|
The Future of Metabolomics Building competitive advantage in drug discovery, clinical development and diagnostics |
August 2006 | £1495 | 12.6 % |
|
Approaches to Reducing Phase II Attrition |
May 2009 | £2475 | 11.2 % |
|
SQI Diagnostics Inc. Product Pipeline Analysis |
August 2008 | £495 | 11.2 % |
|
Biotech Business: May 2005 |
May 2005 | £17 | 11.2 % |
|
Cardiac Markers Clinical Trial Analysis |
July 2009 | £660 | 10.85 % |
|
Cardiac Marker Diagnostic Testing Markets |
May 2008 | £2245 | 10.5 % |
|
Molecular Imaging in Drug R&D and Medical Practice Technologies, Applications, Markets |
January 2008 | £745 | 10.5 % |
|
Multiplexed Diagnostics 2008 |
May 2008 | £2350 | 10.15 % |
|
Disease Specific Markers Clinical Trial Analysis |
July 2009 | £660 | 9.8 % |
|
The Vulnerable Plaque, 2nd edition |
April 2007 | £210 | 9.8 % |
|
Companion Diagnostics in Personalized Medicine and Cancer Therapy |
April 2008 | £2245 | 9.8 % |
|
The Future of Targeted Therapeutics Key Technologies, New Therapy Area Applications and Leading Players |
March 2008 | £1995 | 9.5 % |
|
Cancer Personalized Medicine 2008 |
July 2008 | £2425 | 9.45 % |
|
Tumour Markers Clinical Trial Analysis |
July 2009 | £660 | 9.45 % |
|
Innovations In Epigenetics Advances in Technologies, Diagnostics & Therapeutics |
November 2009 | £3835 | 9.45 % |
|
Multiplex Assays in Translational Medicine Technologies, Applications, and Future Directions |
February 2008 | £745 | 9.1 % |
|
Nanotechnology Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics |
January 2008 | £1995 | 9 % |
|
Cytogenetics Technologies, Markets and Companies |
March 2010 | £1455 | 8.75 % |
|
Hormone Related Testing Reagents Clinical Trial Analysis |
July 2009 | £660 | 8.75 % |
|
bioMerieux S.A. Product Pipeline Analysis |
May 2008 | £495 | 8.75 % |
|
Winning R&D Productivity Strategies Exploiting innovation, licensing and outsourcing opportunities |
October 2006 | £1495 | 8.5 % |
|
Stakeholder Opinions: Osteoarthritis Preconceptions Damage Awareness and Treatments |
March 2006 | £1450 | 8.4 % |
|
Why Do Drugs Fail? |
November 2008 | £995 | 8.05 % |
|
Regulator Perceptions in Cancer Evolving opinions about the oncology drug approval process |
November 2006 | £660 | 8.05 % |
|
Quadraspec, Inc. - Strategic Analysis Review |
June 2009 | £83 | 8 % |
|
Epigenomics AG Product Pipeline Analysis |
August 2008 | £495 | 7.7 % |
|
The Epigenetics Healthcare R&D, Products and Commercial Implications Tools, Technologies, Equipment, Opportunities & Emerging WW Market Outlook |
January 2009 | £1515 | 7.5 % |
|
MicroRNA Research Tools 2008 |
January 2008 | £1540 | 7.5 % |
|
Avalon Pharmaceuticals, Inc. - Financial and Strategic Analysis Review |
July 2009 | £83 | 7 % |
|
Gene Expression Profiling Markets |
January 2008 | £2640 | 7 % |
|
Med BioGene Inc. - Financial and Strategic Analysis Review |
June 2009 | £83 | 7 % |
|
Commercializing Molecular Diagnostics: Products, Services, Companies and Global Market |
July 2008 | £1715 | 7 % |
|
Innovative Clinical Trial Design and Management Trends, Success Stories and Impact upon R&D Budgets |
May 2008 | £1995 | 6.65 % |
|
Cancer Drug Resistance 2008 |
September 2008 | £1675 | 6.65 % |
|
Competitor Analysis: PSMA & PSA Targeted Therapy |
January 2010 | £135 | 6.5 % |
|
Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
February 2007 | £1495 | 6.3 % |
|
IT Software Tools for Life Science and Drug Discovery Bioscience, Biotechnology, Pharmaceutical Company and Institute's IT Software Tools, Strategy, and WW Market Outlook |
June 2009 | £1515 | 6.3 % |
|
Proteomics Technologies, Markets and Companies |
March 2010 | £2970 | 6.3 % |
|
Strategic Analysis of Optical Imaging Technologies in U.S. Clinical Diagnostics and Drug Discovery Markets |
March 2009 | £3965 | 6 % |
|
Bioarrays for Life Science Research, Diagnostics and Drug R&D |
August 2009 | £1650 | 6 % |
|
Transforming Drug Discovery through Genomics and Proteomics |
January 2009 | £395 | 5.95 % |
|
Human Embryo Evaluation and Selection |
August 2007 | £145 | 5.95 % |
|
Stakeholder Opinions: Asthma Phenotypes A changing paradigm |
March 2007 | £1325 | 5.95 % |
|
Johnson & Johnson: Pharma Growth Strategy How does the world's 7th largest pharma company plan to grow its pharmaceutical revenues? |
July 2009 | £245 | 5.95 % |
|
Proteomics International Market Trends |
November 2009 | £1980 | 5.6 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
October 2009 | £1980 | 5.6 % |
|
Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in Personalized Medicine) |
June 2008 | £1980 | 5.6 % |
|
Alzheimer Disease New Drugs, Markets and Companies |
May 2009 | £1850 | 5.6 % |
|
Molecular Diagnostics A Dynamic and Rapidly Broadening Market Overview |
January 2009 | £2475 | 5.6 % |
|
Alzheimer's disease New Drugs, Markets and Companies |
October 2009 | £1980 | 5.6 % |
|
200 China-based Best CROs and CMOs |
March 2009 | £990 | 5.6 % |
|
Stakeholder Insight: Atherosclerosis HDL, ApoA-I, Carotid MRI and 64-slice CT offer opportunities for future treatment |
December 2006 | £5285 | 5.6 % |
|
Drug Targets for Breast Cancer |
January 2006 | £1095 | 5.6 % |
|
Targeting Cancer Stem Cells Emerging Therapeutic, Therapeutic Strategies and Pipeline Developments (2010) |
January 2010 | £1599 | 5.5 % |
|
Roche: Prospects to 2010 Pipeline, Products,Performance,Potential |
September 2007 | £595 | 5.5 % |
|
Biochips Industry forecasts for 2012 & 2017 |
October 2008 | £3040 | 5.5 % |
|
Impact of Pharmacogenomics on Public Healthcare Policy Educating Patients, Payors and Healthcare Providers |
March 2008 | £1995 | 5.25 % |
|
Toxicology and Pharmacology Outsourcing, History, Process and Regulation; Technical, Political and Economic Challenges |
January 2009 | £595 | 5.25 % |
|
Alzheimer's disease New drugs, markets and companies |
December 2008 | £1980 | 5.25 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
February 2010 | £2115 | 5.25 % |
|
Alzheimer's disease |
March 2010 | £2115 | 5.25 % |
|
Nanotechnology in Health Care to 2009 |
May 2005 | £2775 | 4.9 % |
|
Pharmacodiagnostics and Personalized Medicine 2009 (Markets, Challenges, Forecasts and Key Players) |
April 2004 | £2310 | 4.9 % |
|
Epigenetics |
February 2010 | £2970 | 4.9 % |
|
Personalized Medicine Scientific & Commercial Aspects |
March 2010 | £2640 | 4.9 % |
|
In Vitro Diagnostics Market Report & Analysis 2008-2023 |
June 2008 | £1499 | 4.9 % |
|
Stakeholder Opinions: Percutaneous Coronary Intervention Adverse events with drug-eluting stents demand a new safety standard |
April 2008 | £1320 | 4.9 % |
|
Breast Cancer Drug Discoveries What the future holds |
December 2008 | £795 | 4.55 % |
|
The Future of Biobanks Regulation, ethics, investment and the humanization of drug discovery |
March 2009 | £2025 | 4.55 % |
|
Exiqon AS Product Pipeline Analysis |
May 2008 | £495 | 4.55 % |
|
SensiGen, LLC. Product Pipeline Analysis |
August 2008 | £495 | 4.55 % |
|
Biomedical Imaging From Drug Target Discovery to Medical Diagnostics |
December 2008 | £2475 | 4.55 % |
|
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis |
November 2009 | £985 | 4.55 % |
|
DNA Sequencing Technologies, Markets and Companies |
March 2010 | £1190 | 4.55 % |
|
In Vitro Diagnostics Market Analysis 2009-2024 |
May 2009 | £1499 | 4.5 % |
|
Medical Weekly Deals Summaries 18 May 2009 |
May 2009 | £83 | 4.2 % |
|
Molecular Diagnostics 2007 Technologies, Companies, Products, Applications and Worldwide Outlook |
May 2007 | £1515 | 4.2 % |
|
Global Clinical Trial Business Report & Analysis 2008-2018 |
July 2008 | £1499 | 4.2 % |
|
Qiagen N.V. Product Pipeline Analysis |
August 2008 | £495 | 3.85 % |
|
What's Hot in Cancer Drug R&D? |
July 2006 | £295 | 3.85 % |
|
Incremental Improvements And Paradigm Shifts In Strategy Are Both Necessary To Boost Productivity R&D Strategies |
August 2007 | £5020 | 3.85 % |
|
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
November 2006 | £3965 | 3.5 % |
|
Stakeholder Insight: Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines |
December 2006 | £5285 | 3.5 % |
|
Biologic Imaging Reagents Technologies and Global Markets |
December 2008 | £3205 | 3.15 % |
|
Microarray Markets |
September 2008 | £1320 | 3.15 % |
|
Personalized Medicine |
August 2007 | £1320 | 3.15 % |
|
Molecular Diagnostics Technologies, Markets and Companies |
March 2010 | £3300 | 3.15 % |
|
The Executive Guide to Molecular Imaging |
July 2007 | £595 | 3.15 % |
|
High-Growth Diagnostic Testing Markets |
November 2008 | £2245 | 3.15 % |
|
Global Medical Markets for Nanoscale Materials and Devices |
January 2008 | £3205 | 3.15 % |
|
HighGrowth Diagnostic Markets |
November 2008 | £2245 | 3.15 % |
|
Siemens Healthcare Medical Device Company Intelligence Report |
August 2009 | £295 | 3.15 % |
|
Innovations in Diagnostics |
September 2006 | £1495 | 3.15 % |
|
Renal Cancer Drug Pipeline Update 2009 |
May 2007 | £1345 | 3 % |
|
World Market for Molecular Diagnostics, The |
January 2009 | £2640 | 3 % |
|
Cancer Diagnostic Testing World Markets |
April 2008 | £2245 | 2.8 % |
|
Systems Biology A Disruptive Technology |
May 2008 | £745 | 2.8 % |
|
Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
April 2008 | £3965 | 2.8 % |
|
Stakeholder Opinions: Heart Failure When drugs do not work |
April 2008 | £1320 | 2.8 % |
|
Gene Expression Reagents Markets |
April 2007 | £1320 | 2.8 % |
|
Advances in Molecular Imaging Companies and Technologies that are driving change |
February 2010 | £695 | 2.8 % |
|
Medical Imaging Markets: MRI (Magnetic Resonance Imaging) and Ultrasound |
August 2009 | £2310 | 2.8 % |
|
Siemens Medical Solutions Medical Device Company Intelligence Report |
February 2007 | £395 | 2.8 % |
|
Parkinson's Disease Market analysis and forecasts 2008-2012, 2017 & 2022 |
January 2008 | £1499 | 2.8 % |
|
Nitric Oxide Therapeutics, Markets and Companies |
March 2010 | £1850 | 2.8 % |
|
Cell Therapy Technologies, Markets and Companies |
March 2010 | £3300 | 2.8 % |
|
In Vitro Diagnostics in a Recession IVD Market Forecasts, Analysis and Success Strategies |
May 2009 | £1980 | 2.8 % |
|
Renal Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 | 2.5 % |
|
The Pharmaceutical Industry 2008 Current and Future Trends and Strategic Issues Shaping Pharma |
March 2008 | £1980 | 2.45 % |
|
Live-Licensing & In-life Testing R&D Processes and Regulation for New Drugs, 2008-2020 |
January 2008 | £1499 | 2.45 % |
|
Disease Specific Test Reagents Clinical Trial Analysis |
July 2009 | £660 | 2.45 % |
|
Clinical Trials: World Market 2009-2024 |
July 2009 | £1499 | 2.45 % |
|
Decoding Big Pharma's R&D Strategy in Oncology |
September 2007 | £1755 | 2.45 % |
|
Genomics World Markets |
May 2008 | £2245 | 2.1 % |
|
Neuroprotection Drugs, Markets and Companies |
March 2010 | £2970 | 2.1 % |
|
Protein Therapeutics Market; The The Science and Business of a Growing Sector |
June 2006 | £2575 | 2.1 % |
|
DNA Sequencing and PCR Markets |
July 2008 | £2245 | 2.1 % |
|
RNAi Technologies, Markets and Companies |
March 2010 | £2310 | 2.1 % |
|
Commercial Insight Top 20 Cancer Therapeutics |
July 2006 | £5745 | 2.1 % |
|
Innovative Drug R&D in China |
October 2009 | £1910 | 2.1 % |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £1980 | 2.1 % |
|
2007 The Worldwide Biochip & Equipment Market |
August 2006 | £1185 | 2.1 % |
|
The Market for In Vitro Toxicology Testing |
March 2007 | £3205 | 2.1 % |
|
Top 10 Biotech Companies Market Outlook, 2008-2023 |
December 2008 | £1499 | 2.1 % |
|
Animal Biotechnology Technologies, Markets and Companies |
March 2010 | £1650 | 2.1 % |
|
Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment |
June 2007 | £5020 | 2.1 % |
|
Central and Core Laboratories |
October 2007 | £995 | 2.1 % |
|
The Cancer Market Outlook To 2014 Competitive landscape, market size, pipeline analysis and growth opportunities |
January 2010 | £3835 | 2.1 % |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £1980 | 2.1 % |
|
The Future of Metabolic Disorder Therapeutics Market Forecasts to 2015 |
December 2009 | £2310 | 2.1 % |
|
The Top 10 Contract Research Organizations Positioning, performance and SWOT analyses |
March 2009 | £2025 | 2.1 % |
|
Stakeholder Opinions: Cancer Cachexia Higher profile needed to unlock market potential of neglected syndrome |
January 2009 | £1320 | 2.1 % |
|
Next-Generation Nutraceuticals Food and pharma convergence in disease prevention and personalized nutrition |
December 2006 | £1495 | 2.1 % |
|
Cell-Based Assays for Drug Discovery |
August 2009 | £2245 | 2.1 % |
|
Pipeline Insight: Colorectal Cancer Growing trend towards personalized medicine |
October 2009 | £7530 | 1.75 % |
|
Commercial Insight: Antithrombotics Market expands as disease management focuses on prevention |
October 2007 | £5020 | 1.75 % |
|
Stakeholder Opinions: Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success Healthcare |
March 2009 | £1320 | 1.75 % |
|
Early Toxicology Markets and Approaches |
June 2007 | £2310 | 1.75 % |
|
Therapeutic/Diagnostic Devices for Neurological Disorders |
March 2007 | £3205 | 1.75 % |
|
Genetic Test Reagents Clinical Trial Analysis |
July 2009 | £660 | 1.75 % |
|
Biotech in Autoimmune and Inflammatory Disease 2006 2nd Edition |
May 2006 | £1980 | 1.75 % |
|
Direct-To-Consumer Genetic Testing Business Prospects in the United States |
March 2009 | £2475 | 1.75 % |
|
Infectious Immunology Test Reagents Clinical Trial Analysis |
July 2009 | £660 | 1.75 % |
|
Therapeutics for Memory and Cognition Disorders |
April 2009 | £3205 | 1.75 % |
|
Drug Delivery in Cancer Technologies, Markets and Companies |
March 2010 | £2310 | 1.4 % |
|
Oncology Market Leaders Analyses and Outlook, Market Report 2008 - 2023 |
October 2008 | £1499 | 1.4 % |
|
Preclinical Cancer Therapeutics 2007 Decoding Next Generation Drug Targets for Market Success |
December 2006 | £1600 | 1.4 % |
|
Medical Nanotechnology Markets |
September 2008 | £2245 | 1.4 % |
|
Pain Therapeutics Drugs, Markets and Companies |
March 2010 | £2310 | 1.4 % |
|
Pipeline Insight: Breast Cancer Recent approvals increase pressure on pipeline candidates |
April 2008 | £3965 | 1.4 % |
|
Drug Delivery to CNS |
March 2010 | £1850 | 1.05 % |
|
Drug Delivery to Central Nervous System Diseases Technologies, Markets and Companies |
February 2010 | £1850 | 1.05 % |
|
Nanobiotechnology Applications, Markets and Companies |
March 2010 | £2970 | 1.05 % |
|
Nanobiotechnology |
February 2010 | £2940 | 1.05 % |
|
Drug Delivery in Central Nervous System Diseases Technologies,Markets and Companies |
October 2009 | £1650 | 1.05 % |
|
How Drugs Are Developed 3rd Edition |
January 2007 | £1095 | 1.05 % |
|
The Worldwide Market for In Vitro Diagnostic Tests 6th Edition [with 2009 Economy Preface] |
May 2008 | £2640 | 1.05 % |
|
Instruments Clinical Trial Analysis |
July 2009 | £660 | 1.05 % |
|
Pipeline and Commercial Insight: Osteoporosis Novel agents to battle for payer acceptance |
July 2009 | £10040 | 1.05 % |
|
Antiviral Therapeutics Technologies, Markets and Companies |
March 2010 | £2115 | 1.05 % |
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline |
October 2006 | £5285 | 0.7 % |
|
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008 |
May 2007 | £280 | 0.7 % |
|
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2009 / 2010 |
June 2009 | £280 | 0.7 % |
